HHS will let pharmacies compound six unapproved peptides, for now

What happened

HHS has released a policy that will "temporarily" let compounding pharmacies make some peptide products, as first reported by STAT (STAT). STAT describes the products as experimental wellness therapies embraced by the MAHA movement.

The mechanism is called enforcement discretion. HHS says it will not act against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides previously backed by an FDA advisory committee.

In plain terms, the products stay unapproved. The government is simply saying it won't come after the people making them, at least for a while.

What the notice says, and what we haven't seen

The policy sits in the Federal Register's public-inspection system as document 2026-22192. The peptide list is in HHS's Appendix B.

We could not read either document, and STAT's story is paywalled past its opening paragraphs. What follows about the policy's wording comes from that lead. We have not verified the exact peptide names, any conditions on use, the end date or the legal citations.

An earlier STAT report said HHS had sent an "interim access policy" to the White House Office of Management and Budget. Two unnamed sources told that outlet the policy was meant to cover popular peptides, including BPC-157. The Oct. 28 lead says only that it covers the six the advisory committee backed, so whether BPC-157 is on the list needs checking against Appendix B.

The advisory vote behind the list

FDA's Pharmacy Compounding Advisory Committee met July 23 and 24, 2026, to weigh adding peptides to the section 503A bulk drug substances list. STAT's coverage reported these votes. The count of six backed peptides matches the policy lead, though we haven't confirmed the lists are identical.

STAT said most yes-voting panelists had ties to the peptide industry and were appointed by HHS. The dissenters were largely academic physicians and patient representatives. Some yes-voters argued they were not approving a drug, so they didn't need to weigh the lack of robust clinical data.

For each peptide, FDA staff recommended against allowing compounding because of a lack of clinical evidence of safety and efficacy. They also said that once a substance is on the 503A list, the agency cannot require compounders to submit safety or efficacy data.

What this does not show

A vote and an enforcement policy are not evidence that these products work or are safe. Take BPC-157, the best known. STAT's February explainer says almost all of its data comes from a single Croatian research group. In rodents it promotes blood-vessel growth and reduces inflammation, with few side effects documented.

A systematic review in orthopaedic sports medicine reports no microscopic organ changes in rat and dog models through 6 weeks, and no toxic or lethal dose across 6 μg/kg to 20 mg/kg. It also says human safety "was not assessed in the included studies and thus remains unknown." We saw only a snippet, so check the full paper for study count and design.

• FDA's category 2 list of bulk substances with potential significant safety risks includes BPC-157, citing immunogenicity concerns for certain routes and peptide-related impurities.
• An FDA briefing document says the agency cannot rule out immunogenicity from impurities or peptide aggregates, and that stability and activity are highly sensitive to formulation and manufacturing.
• Semax is reported to be approved for clinical use in Russia, but FDA staff still found the evidence insufficient for the conditions proposed. FDA staff still found the evidence insufficient for the conditions proposed.

We also don't know how compounders will be monitored or how adverse events will be tracked. FDA staff said they cannot require safety data once a substance is listed, and we haven't seen what the new policy requires.

What it means for you

Expect more peptides may be offered by telehealth clinics and pharmacies. Legal to compound does not mean tested. Nothing here changes the evidence on whether these products do what wellness accounts claim.

• Talk to a licensed clinician who knows your health history, especially if you take other medications or have an autoimmune or inflammatory condition.
• Ask where the product is made. The policy covers state-licensed pharmacies, federal facilities and licensed physicians, not random online sellers.
• Ask what human evidence exists for your specific use. For most of these, the honest answer is very little.
• Be wary of any seller who frames the policy as proof of safety or effectiveness.

Secretary Kennedy has argued that compounding pharmacies must be allowed to sell peptides because, as Kennedy has argued, many Americans buy gray-market versions made in China and elsewhere. That is a real concern about quality control. It is not evidence that the compounded versions are effective.

Context: a workaround for a slow process

Formal listing on the 503A bulks list requires federal rulemaking, which could take years and involves multiple rounds of public comment. STAT's earlier reporting said it was unclear whether the administration still planned to pursue it. Enforcement discretion skips that wait.

Critics see a larger problem. A JAMA Viewpoint by Samantaroy, Xu and Lurie, published online Oct. 26, says compounding these peptides could be a profound threat to FDA drug approval. We saw only the abstract and opening. We also did not find formal statements from medical or pharmacy societies.

We will update this piece once the Federal Register notice and Appendix B can be read in full.